Cookie use on MRCVSonline
We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive all cookies.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Aservo® EquiHaler® now available in the UK and Ireland
The inhaler marks more than a decade of collaboration between human pharma and animal health businesses.

Product allows medication to be inhaled deep into horses’ lungs.
 
The first inhaled treatment for severe equine asthma is now available in the UK and Ireland.

Manufactured by Boehringer Ingelheim, the Aservo® EquiHaler® marks more than a decade of collaboration between human pharma and Boehringer’s animal health business.

The inhaler incorporates Soft Mist Technology®, which is found in the Respimat® inhaler used in human respiratory disease. This allows the active ingredient to be inhaled deep into the horses’ lungs.

"It's another industry first and is a strong indicator of the commitment that Boehringer Ingelheim has to the health and welfare of horses, and to the investment that we make into continuing to advance therapies through collaboration and innovation,” commented Dr Marc Laemmer, head of equine in UK & Ireland.

“We understand that a product launch in this challenging time for the veterinary profession may seem surprising, but we have had such strong demand from equine vets for the product that we have committed to making Aservo® EquiHaler® available. Our team of territory managers and vet advisers will conduct remote meetings with customers to make sure that they have the information and support they require.”

He continues: “The launch of Aservo® EquiHaler® is a prime example of leveraging innovation efforts of both our human and animal businesses. This has been a strength of ours and I'm excited that we are continuing to further increase the delivery of innovative solutions for horse owners and vets."

The active ingredient in the Aservo® EquiHaler® is ciclesonide - a corticosteroid that is activated directly in the lung, reducing the lower airway inflammation associated with severe equine asthma and reducing the risks commonly associated with systemic corticosteroids.

It does not use a propellant, meaning that using the device does not contribute to harmful greenhouse gas emissions. It has also been manufactured from 50 per cent recycled materials.

Featuring an ergonomic handle, dosing lever, and nostril adapter, the Aservo® EquiHaler®  has been awarded the prestigious Red Dot Award for Product Design.



Become a member or log in to add this story to your CPD history

MSD Animal Health announces three new research bursaries

News Story 1
 MSD Animal Health has announced three new research bursaries for veterinary surgeons in the areas of swine, poultry and aquaculture. The bursaries, worth up to £4,000, add to MSD's existing bursaries in ruminant and companion animal research.

Projects are expected to be completed within one to two years, and the proposals will be judged by university academics to ensure that assessment remains independent. Full project design and application guidelines, including the specific disease/subject areas, can be found on MSD Animal Health's website

Click here for more...
News Shorts
VMD and VPS announce joint open information day

The Veterinary Medicines Directorate (VMD) and the Veterinary Products Committee (VPC) have announced a joint open information day covering topics such as veterinary medicines regulations, antimicrobial resistance, scientific advice and novel therapies.

Taking place on Wednesday 18 November, the virtual event will take the form of a series of pre-recorded webinars and a 'Slido' Q&A session. Links to the webinars and full instructions on how to use Slido will be available on gov.uk on 18 November. To join the mailing list for the event, email director.support@vmd.gov.uk